| For: | Elsayed MOK. Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives. World J Gastrointest Oncol 2025; 17(11): 110735 [PMID: 41281491 DOI: 10.4251/wjgo.v17.i11.110735] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i11/110735.htm |
| Number | Citing Articles |
| 1 |
Sarina Ailawadi, Sepideh Mehravar, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal. Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. Biomedicines 2026; 14(7) doi: 10.3390/biomedicines14071638
|
| 2 |
Hanan R. H. Mohamed, Sara A. Diab, Jana W. Mofadal, Yasmine W. Hamdy, Bassema E. Elnewihy, Bassant Haitham, Basma M. I. El-Sherif, Ayman Diab, Gehan Safwat. MTA-NPs induce preferential cytotoxicity, oxidative DNA damage, and mitochondrial apoptosis in human Hep-G2 hepatocellular carcinoma cells. Naunyn-Schmiedeberg's Archives of Pharmacology 2026; doi: 10.1007/s00210-026-05581-6
|